Who we are
A unique force in the pharmaceutical industry
Merck Serono combines its complementary expertise in new chemical entities (NCEs) and new biological entities (NBEs) to offer
innovative prescription drugs of either origin.
With comprehensive skills in all areas from research and development to manufacturing, marketing and sales, the division offers
its world-class products in over 150 countries worldwide. Our strategically positioned workforce of 9,000 sales and marketing
employees ensures commercial coverage in the U.S. and Canada, Latin America, Europe, Asia-Pacific and Japan.
We aim to
-
Become a world leader in health technology
-
Support the healthcare community to understand the technologies and to maximise the health gain for our patients
We will invest resources to ensure support in the following areas
-
Genetic testing to identify responders to therapies
-
Technologies to enhance adherence
-
Nurse programmes to support patients
In the UK
-
Patients are our focus
-
Healthcare Decision Makers are our priorities’
-
Improved Healthcare is our Goal
Merck Serono UK are developing a legacy:
‘What we do with our technologies has a direct impact on you and your patients.’
‘What we do with our technologies has a direct impact on you and your patients.’
Neurodegenerative diseases
For product information please click on the below links:Fertility
For product information please click on the below links:Endocrinology – Saizen®, Kuvan®
Merck Serono was a pioneer in making recombinant human growth hormone available for the treatment of growth hormone deficiency
in children and adults (Saizen). With the recently announced European marketing authorization with Kuvan® (sapropterin dihydrochloride), Merck Serono offers
the only treatment indicated in Europe for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) in patients
over the age of 4; or due to tetrahydrobiopterin BH4 deficiency.
For product information please click on the below links:
